

Dr. Henning Gädeke,
Chair of the Global Health EDCTP3 Joint Undertaking Governing Board
c/o Dr. Michael Makanga,
Global Health EDCTP3 Joint Undertaking Executive Director
Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d'Or
1060 Brussels
Belgium

August 29, 2025

Letter of endorsement: *Advancing A Vaccine for Adolescent/Adult and Neonatal TB Epidemic (MTBVAC-AVANTE)*

Dear Drs., Gädeke and Makanga,

On behalf of IAVI and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application of IAVI Inc., located at 125 Broad St 9th floor, New York, NY 10004, United States, to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

IAVI is a non-profit organization dedicated to developing vaccines and antibodies for HIV, tuberculosis, emerging infectious diseases, and neglected diseases. Our mission is to translate scientific discoveries into affordable, globally accessible public health solutions.

Like EDCTP, IAVI is dedicated to developing products that meet the health needs of countries in Sub-Saharan Africa, to ensuring that these products can ultimately be affordable and accessible to all people who need them, to building and supporting sustainable capacity for health research, and to facilitating cross-regional and multidisciplinary partnerships. As such, IAVI and EDCTP share a long history of collaboration, dating back to EDCTP1. Most recently, IAVI experts have collaborated with EDCTP to develop the clinical trial site directory for TB vaccines, the global roadmap for the development of new vaccines against tuberculosis and conducting effective early and late-stage TB vaccine trials across multiple sites in sub-Saharan Africa.

For over 20 years, IAVI has worked with research partners in East, Southern and West Africa to conduct epidemiology research and build and strengthen research capacity in areas with high burden of disease, including HIV/AIDS, TB and Lassa Fever. Our work directly contributes to the achievement of the objectives of Global Health EDCTP3 JU, such as enhancing clinical research capacity for conducting current and future clinical studies at high-quality international standards, strengthening/expanding multidisciplinary epidemiology networks, nurturing African scientific leadership, fostering North-South collaborations between researchers and institutions offering training and expertise support, and strengthen ethics and regulatory capacities.


In relation to this Letter of Endorsement, IAVI is participating as a partner in the project application *Advancing a Vaccine for Adolescent/Adult and Neonatal TB Epidemic (MTBVAC-AVANTE)* and will be supporting the project through co-funding if the application is successful. IAVI intends to participate in MTBVAC-AVANTE as “contributing partners”, supporting specifically WP4 (a Phase 2b clinical trial in adolescents and adults), with additional support in WP2 (scientific project

leadership), WP5 (regulatory and access) and WP6 (dissemination, exploitations and communications). We estimate the total value of our contribution directly benefiting MTBVAC-AVANTE to be **€ 40.328.252,1 million**. This contribution will be provided as in-kind support covering IAVI staff time, travel and other direct costs, and in-cash contributions for subcontracts and support for clinical research centres in South and Eastern Africa engaged in the Phase 2b MTBVAC trial. The co-funding that IAVI is providing stems from resources provided to IAVI by multiple funders who are supporting core elements of the Phase 2b trial. Additional support from EDCTP, if the application is successful, will enable the expansion of the trial and support work towards achieving an accelerated path to market authorization and broad and equitable access.

With this endorsement letter, we also confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the “need-to-know” principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully,



Mark Feinberg, MD, PhD
President and CEO
mfeinberg@iavi.org

